FDA Approves Zepbound

In a landmark decision, the U.S. Food and Drug Administration (FDA) has officially approved Zepbound (tirzepatide) as the first-ever medication for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. This approval introduces a new approach to managing OSA, providing an alternative or supplementary option for patients who have struggled … Read more